Crinetics Pharmaceuticals Stock Price, News & Analysis

Crinetics Pharmaceuticals (CRNX) has appointed Tobin 'Toby' Schilke as Chief Financial Officer, effective February 28, 2025. Schilke brings over 25 years of global pharmaceutical experience and will succeed Marc Wilson. In his previous role as CFO at Revance Therapeutics, he managed finance and operations for a 650-employee company, achieving over $700 million in cumulative revenue across two product launches.

At Achaogen, Schilke built various operational functions and executed over $1.5 billion in financing deals. He previously held increasing roles at Roche/Genentech. As part of his compensation package, Schilke will receive 52,000 restricted stock units and options to purchase 80,000 shares, vesting over four years, granted under the company's 2021 Inducement Plan.

Crinetics Pharmaceuticals (CRNX) has announced its participation in two major healthcare investor conferences in March 2025. The company will be present at the TD Cowen 45th Annual Healthcare Conference in Boston, where management will participate in a fireside chat on March 3 at 11:10 a.m. ET. Additionally, they will attend the Leerink Global Healthcare Conference in Miami, featuring another fireside chat on March 10 at 4:20 p.m. ET.

Both events will be available via webcast, with live and archived versions accessible through the Events & Presentations page in the Investors section of Crinetics' website. Investors interested in one-on-one meetings with management are encouraged to contact their conference representatives.

Crinetics Pharmaceuticals (CRNX) has announced new equity grants under its 2021 Employment Inducement Incentive Award Plan. The company's Compensation Committee approved non-qualified stock options to purchase 105,100 shares and 9,950 restricted stock units (RSUs) for 14 new non-executive employees on February 10, 2025.

The stock options were priced at $36.53 per share, matching CRNX's closing price on the Nasdaq Global Select Market. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest in equal annual installments over four years. Both grants are contingent on continued employment and were made in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals (CRNX) has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, February 27, 2025, after market close. The company will host a conference call at 4:30 p.m. ET, featuring management discussion of financial results and a business update.

Interested parties can join via phone using domestic (1-800-267-6316) or international (1-203-518-9783) dial-in numbers with Conference ID: CRNXQ4. Alternatively, participants can access a live webcast through the Events section of Crinetics' website. Participants are advised to connect 15 minutes before the call. The webcast will be archived on the company's Investor Relations section.

Crinetics Pharmaceuticals (CRNX) has announced new stock option grants under its 2021 Employment Inducement Incentive Award Plan. The company granted options to purchase 96,100 shares to sixteen new non-executive employees and 100,000 shares to one new executive employee on January 10, 2025.

The options were granted at an exercise price of $40.59 per share, matching Crinetics' closing price on The Nasdaq Global Select Market. The vesting schedule spans four years, with 25% vesting after one year and the remaining shares vesting in 36 equal monthly installments, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement awards for new employees.

Crinetics Pharmaceuticals (CRNX) announced positive topline results from its Phase 2 trial of atumelnant for Congenital Adrenal Hyperplasia (CAH). The study, involving 28 patients across 3 dose cohorts, demonstrated substantial and statistically significant reductions in key biomarkers, including up to 80% mean reduction of androstenedione.

The trial showed meaningful improvements in CAH symptoms, with notable results including: testosterone normalization in majority of female participants, consistent reduction in total adrenal volume, and resolution of androgen mediated polycythemia in most affected participants. Atumelnant was generally well-tolerated, with no treatment-related severe adverse events or discontinuations.

Based on these positive results, Crinetics plans to proceed with a global Phase 3 pivotal trial for adults and prepare for a Phase 2b/3 trial in pediatric patients this year.

Crinetics Pharmaceuticals (Nasdaq: CRNX) has announced that its Founder and CEO, Scott Struthers, Ph.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference. The event will take place in San Francisco, CA on Tuesday, January 14, 2025, at 4:30 p.m. Pacific Time.

To access the live webcast of the presentation, interested parties can click a provided link. Additionally, the archived webcast will be available on the Events & Presentations page in the Investors section of Crinetics' website at www.crinetics.com/events.

For those who wish to arrange a 1x1 meeting with the management, it is advised to contact their conference representative.

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will oversee the commercial strategy and operations for the potential launch of paltusotine and pre-commercialization activities for the company's pipeline.

Scott Struthers, CEO, praised her vast expertise in launching therapies and leading commercial strategies. Ms. Kalofonos expressed enthusiasm for joining Crinetics, emphasizing her commitment to building a top-tier commercial team and advancing treatments for acromegaly and other endocrine disorders.

Ms. Kalofonos brings over 20 years of experience in the pharmaceutical and biotech industry, having held senior roles at ImmunoGen, Galderma, and Takeda Pharmaceuticals. She has a proven track record in launching breakthrough therapies, including ELAHERE and TAKHZYRO.

On January 10, 2025, Crinetics will grant Ms. Kalofonos a stock option to purchase 100,000 shares, with specific vesting conditions under the 2021 Employment Inducement Incentive Award Plan.

Crinetics Pharmaceuticals (CRNX) has granted non-qualified stock options to sixteen new non-executive employees under its 2021 Employment Inducement Incentive Award Plan. The options allow purchase of 146,400 shares at an exercise price of $57.17 per share, matching CRNX's closing price on Nasdaq Global Select Market on December 10, 2024. The stock options will vest over four years, with 25% vesting after one year and the remainder vesting in 36 monthly installments, contingent on continued employment. These grants comply with Nasdaq Listing Rule 5635(c)(4) as inducement awards for new employees.